Aeglea BioTherapeutics Appoints Dr. Ivana Magovčević-Liebisch to Board of Directors
26 mars 2018 08h00 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, March 26, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference
20 mars 2018 08h00 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, March 20, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results
13 mars 2018 07h00 HE
|
Aeglea BioTherapeutics, Inc.
Repeat Doses of Company’s Pegzilarginase Produces Marked and Sustained Reductions in Plasma Arginine Levels Accompanying Reductions in Other Related Guanidino Compounds Also Seen Additional...
Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase
08 mars 2018 08h00 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, March 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders
06 mars 2018 16h21 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, March 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference
18 janv. 2018 16h05 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme...
Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
07 déc. 2017 16h05 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme...
Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)
29 nov. 2017 08h00 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme...
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
07 nov. 2017 16h05 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting
02 nov. 2017 16h07 HE
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...